In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance

Ryan M. Pearson, Liam M. Casey, Kevin R. Hughes, Stephen D. Miller*, Lonnie D. Shea

*Corresponding author for this work

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

Technologies that induce antigen-specific immune tolerance by mimicking naturally occurring mechanisms have the potential to revolutionize the treatment of many immune-mediated pathologies such as autoimmunity, allograft rejection, and allergy. The immune system intrinsically has central and peripheral tolerance pathways for eliminating or modulating antigen-specific responses, which are being exploited through emerging technologies. Antigen-specific tolerogenic responses have been achieved through the functional reprogramming of antigen-presenting cells or lymphocytes. Alternatively, immune privileged sites have been mimicked using biomaterial scaffolds to locally suppress immune responses and promote long-term allograft survival. This review describes natural mechanisms of peripheral tolerance induction and the various technologies being developed to achieve antigen-specific immune tolerance in vivo. As currently approved therapies are non-specific and carry significant associated risks, these therapies offer significant progress towards replacing systemic immune suppression with antigen-specific therapies to curb aberrant immune responses.

Original languageEnglish (US)
Pages (from-to)240-255
Number of pages16
JournalAdvanced Drug Delivery Reviews
Volume114
DOIs
StatePublished - May 15 2017

    Fingerprint

Keywords

  • Allergy
  • Autoimmune disease
  • Drug delivery
  • Immune tolerance
  • Nanoparticle
  • Regulatory T cells
  • Transplantation

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this